As-needed (intermittent) inhaled corticosteroid for mild asthma
|
|
- Cathleen Miller
- 5 years ago
- Views:
Transcription
1 CIPP VIII 8 th International Congress on Pediatric Pulmonology, Nice 2008 As-needed (intermittent) inhaled corticosteroid for mild asthma Tari Haahtela, Professor Skin and Allergy Hospital, Helsinki University Central Hospital, PO Box 160, HUS, Finland tari.haahtela@hus.fi
2 2 Asthma is a syndrome Both in children and adults, asthma is a syndrome, an umbrella diagnosis. It is a variable (chronic), inflammatory condition of the lower airways characterized by largely reversible airflow obstruction, airway hyperresponsiveness, and episodic respiratory symptoms, including wheezing, productive cough, and sensations of breathlessness and chest tightness. Asthma covers several genotypes in terms of factors affecting disease severity or responses to treatments and drugs. Most of asthma is mild At the population level most of asthma is intermittent or mild (70-80%), and more often so in children compared to adults. These patients are probably not facing any significant lung function loss over time even regardless their treatment. More attention should be paid on the mild end of the asthma spectrum, to the majority of patients to estimate better the treatment impact on different disease outcomes: symptom persistence, lung function loss over time, and need for regular medication. Under-treatment is still a major problem, but unnecessary or even harmful over-treatment is also becoming common. Strategies to treat mild asthma are not well based on evidence, neither in children nor adults. How intensive should the initial treatment be? For how long it should go on, in children and adults? When is intermittent treatment sufficient, and for how long should the treatment periods take? If treatment is altogether stopped by the patient, what is the risk for disease escalation?
3 3 Most asthma drug studies have been accomplished in patients with moderate persistent asthma (to have room for improvement and possibility to show treatment differences), and the results are often carelessly generalized to whole asthmatic population. Along with better options to measure not only lung function but the inflammatory component of asthma [1,2], the early and often milder stages of the disease, when lung function is still mostly preserved, can be better addressed. Asthma may commence already in infancy and continue to adult life, but the inflammation-structure-function relationships in infants have only recently been explored [3]. Decliners are minority There are the lung function decliners, those patients (estimates in adults range from 20-30% of asthmatics) in whom significant irreversible airways obstruction develops over time. The possible slowing down effect of inhaled corticosteroids (ICS) may be seen more readily in them. Recent 10-year observational data from Denmark indicate that may be the case [4]. In a general population sample treatment of asthma with ICS was associated with a less steep decline in FEV1 of 18 ml/year compared with patients not receiving this treatment (p=0.01). The clinical benefits of early treatment with anti-inflammatory therapy for persistent-type, but still mostly mild asthma were shown in the early 1990s [5]. The first results in the mid 1990s also indicated that delays in initiating ICS therapy may lead to an impaired functional response [6]. The non-randomized studies by Agertoft and Pedersen [7] and Selroos et al. [8] pointed to the same direction: delay was harmful. However, the prospective CAMP study questioned the benefit of inhaled corticosteroids on children lung function, but as no significant FEV1 decline was seen in the placebo group, treatment effect was difficult to demonstrate [9].
4 4 Whether ICS alter the long term functional (natural) course of asthma in children or adults is still debated, and may never be fully answered. Length of the follow-up required, ethical considerations and costs will prevent that. These doubts should not, however, hinder us to use the most effective treatment and use it early enough. At least in adults, the results of O`Byrne et al. [10] and Lange et al. [4] reassure our current practice of preventing all asthma events with regular use of ICS the dose can vary in patients who have symptoms on most days. HEICA-study The Helsinki Early Intervention Childhood Asthma Study (HEICA) is a landmark study to show that as-needed treatment may, in fact, be the strategy of choice for most children with mild asthma [11]. The study compared step-down inhaled budesonide given daily or as-needed (intermittently) in mild persistent childhood asthma. 176 children aged 5 10 years with newly detected asthma were randomized into three treatment groups: Group 1: continuous budesonide (400 µg twice daily for 1 month, 200 µg twice daily for months 2 6, 100 µg twice daily for months 7 18); Group 2: budesonide/placebo (identical treatment to Group 1 during Months 1 6, then budesonide for exacerbations as-needed for months 7 18); and Group 3: disodium cromoglycate (DSCG) 10 mg three-times daily for months Exacerbations were treated with budesonide 400 µg twice daily for 2 weeks. Compared with DSCG the initial regular budesonide treatment resulted in a significantly better improvement of lung function, fewer exacerbations and a small but significant decline in growth velocity. After 18 months, however, the lung function improvements did not differ between the
5 5 groups. During months 7-18, children receiving continuous low-dose budesonide treatment (100 µg twice daily) had significantly fewer exacerbations (mean 0.97), compared with 1.69 in Group 2 (budesonide only as needed) and 1.58 in Group 3 (most drop outs from this group, towards the end of the 1 ½ year trial treatment became mixed DSCG and budesonide because exacerbations were treated with budesonide). The number of asthma free days did not differ between regular and intermittent budesonide treatment. Growth velocity was normalized during continuous lowdose budesonide and budesonide therapy given as needed, but the latter was associated with catch-up growth. It was concluded, that regular use of budesonide afforded somewhat better asthma control but more systemic effects than use of budesonide as needed only. The dose of ICS could be reduced as soon as asthma is controlled. The most important observation was, however, that a significant proportion of children with mild asthma (even majority!) does not seem to need continuous ICS treatment. Real-life experience from Finland In 1994, the Finnish asthma program was established to reduce morbidity of asthma in Finland with a focus on early detection and treatment of inflammation, as implemented by a network of asthma-responsible doctors, nurses, and pharmacists. While this program has not halted the increase of asthma in Finland, the burden of asthma has been greatly decreased over 10 years [12]. This outcome can be attributed mainly to early and more effective use of anti-inflammatory medication. Although there is no exact data, it seems that in real life most asthma patients in Fin-
6 6 land, both children and adults do use ICS as needed (intermittently), and this has been partly promoted by the guided self-management strategies in Finland, where increasing and decreasing of the ICS dose, according to symptoms and need for rapid-acting beeta2-agonists, has been taught to the patients. The problem is, of course, that patients (parents) tend to underestimate the severity of the condition (airway inflammation) and the anti-inflammatory treatment is far from optimal. Too liberal attitude to as-needed use of ICS may deteriorate overall asthma control in the population. Nevertheless, well educated and adherent patients (parents) may be able to use as-needed strategy, if they start treatment proactively (early enough) and keep it long enough (4 weeks). This is especially true in many of the children, who tend to become free of symptoms when approaching adolescency. Our recommendation in Finland is at the moment the following. Children with newly diagnosed asthma should be on regular ICS for 6 months, and adults for 12 months. If patients are free of symptoms and with normal lung function (also eno is considered), they may try as-needed approach. If too many exacerbations occur (more than 2 per year) they are put on regular ICS, the dose of which may vary. Conclusions In asthma the relationships of airway inflammation, remodeling and lung function are becoming better understood; they are consecutive but also parallel phenomenons, which vary largely both in severity and timing between individuals. Anti-inflammatory therapy with ICS still remains the
7 7 best option for the vast majority of patients to improve asthma control. The inflammatory element of asthma can be detected more readily than before by measuring exhaled NO, or examining cells and soluble markers in induced sputum. Increased airway responsiveness is a surrogate marker of inflammation and seems to reflect development of structural changes in the airways. Exacerbation rate is reduced, if inflammatory markers - exhaled NO [13], sputum eosinophils or hyperresponsiveness - guide the treatment. New modes of ICS therapy, especially as-needed therapy, have emerged, but are still not well established through clinical trials. Given the similarity that exists between the patterns of inflammation in asthma and allergic rhinitis, treatment should always focus the entire airway rather than only a part, as well as the skin (inflammation in atopic eczema) as necessary.
8 8 References 1. Rytila P, Metso T, Heikkinen K, Saarelainen P, Helenius IJ, Haahtela T. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. Eur Respir J 2000, 16(5): Haahtela T, Tamminen K, Malmberg LP, Zetterström O, Karjalainen J, Ylä-Outinen H, Svahn T, Ekström T, Selroos O. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir. 2006; 28: Saglani S, Malmstrom K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M, Turpeinen M, Rogers AV, Payne DN, Bush A, Haahtela T, Mäkelä M, Jeffery PK. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 2005, 171(7): Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006;61: Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991, 325(6): Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijarvi A et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994, 331(11): Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in children. Respir Med 1994;88: Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs. late intervention with inhaled corticosteroid in asthma. Chest 1995;108: Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343: O Byrne P, Pedersen S, Busse WW, Tan WC, Chen Y-Z, Ohlsson SV, Ullman A, Lamm CJ, Pauwels RA. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006;129: Turpeinen MT, Nikander K, Pelkonen A, Syvänen P, Sorva R, Raitio H, Malmberg P, Juntunen-Backman K, Haahtela T. Daily versus as-needed inhaled corticosteroid for mild persistent asthma. The Helsinki early intervention childhood asthma study (HEICA). Arch Dis Child, published online Jul Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA: A ten-year asthma programme in Finland: A major change for the better. Thorax 2006; 61: Smith AD, Cowan JO, Brasset KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:
Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
Asthma and lower airway disease Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma Tari Haahtela, MD, PhD, a Klaus Tamminen, MD, a Tuomo Kava, MD, PhD,
More informationDaily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study)
See Perspective, p 644 1 Department of Allergy, Helsinki University Hospital, Finland; 2 AstraZeneca R&D, Lund, Sweden Correspondence to: Dr M Turpeinen, Skin and Allergy Hospital, Department of Allergy,
More informationA systematic approach to asthma managament. Finnish Asthma Programme
Helsinki, Norwegian doctors 16. October 2014 A systematic approach to asthma managament. Finnish Asthma Programme 1994-2004 Allergy 2009 Professor Tari Haahtela Skin and Allergy Hospital Helsinki University
More informationRevisiting early intervention in adult asthma
REVIEW ASTHMA Revisiting early intervention in adult asthma Tari Haahtela 1, Olof Selroos 2 and Paul M. O Byrne 3 Affiliations: 1 Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki,
More informationEffect of disease duration on dose response of inhaled budesonide in asthma
Respiratory Medicine (2008) 102, 1065 1072 Effect of disease duration on dose response of inhaled budesonide in asthma Olof Selroos a,b, a Mjölbolsta Hospital, Karis, Finland b SEMECO AB, Skogsvägen 5,
More informationEarly treatment in asthma: How early is early?
Allergology International (2002) 51: 75 83 Review Article Early treatment in asthma: How early is early? Tari Haahtela Division of Allergy, Skin and Allergy Hospital, Helsinki University Central Hospital,
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationTreatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function
Eur Respir J 2008; 32: 989 996 DOI: 10.1183/09031936.00062307 CopyrightßERS Journals Ltd 2008 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationAsma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli
Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.
More informationOutcome, classification and management of wheezing in preschool children Paul L.P. Brand
Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationMethacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges
Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges AAAAI San Antonio Tx February 2013 Catherine Lemière MD, MSc Hôpital du
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationEffect of inhaled budesonide therapy on lung function in schoolchildren born preterm
RESPIRATORY MEDICINE (2001) 95, 565 570 doi:10.1053/rmed.2001.1104, available online at http://www.idealibrary.com on Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationAsthma: Classification, Management, Prevention and New Treatments
Asthma: Classification, Management, Prevention and New Treatments Cori Daines, MD, Professor Pediatric Pulmonary Medicine University of Arizona April 28, 2018 I have no relevant financial relationships
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationAirway inflammation in patients with symptoms suggesting asthma but with normal lung function
Eur Respir J 2; 16: 824±83 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Airway inflammation in patients with symptoms suggesting asthma but
More informationStarting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment
Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment THYS van der MOLEN, BETTY MEYBOOM-DE JONG, HELMA H. MULDER, and DIRKJE S. POSTMA Department of General Practice,
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationAsthma Programme in Finland: Did the use of secondary care resources become more rational?
Respiratory Medicine (2010) 104, 957e965 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Asthma Programme in Finland: Did the use of secondary care resources become more
More informationASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN
More informationEffect of 1 year daily treatment with 400 µg budesonide (Pulmicort Turbuhaler ) in newly diagnosed asthmatics
Eur Respir J 1997; 10: 2210 2215 DOI: 10.1183/09031936.97.10102210 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Effect of 1 year daily
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationClinical Issues Research Implemented April 2010 Asthma Major Recommendations Goals of asthma: - 1) reduction of impairment freedom from symptoms,
Asthma Major Recommendations Goals of : - 1) reduction of impairment freedom from symptoms, such as cough, shortness of breath, wheezing, and disturbed sleep minimal need (< 2 times per week) of short
More informationPaediatric Public Assessment Report EU Work sharing Procedure - Assessment of Paediatric data. Pulmicort Turbuhaler. Powder for inhalation.
Paediatric Public Assessment Report EU Work sharing Procedure - Assessment of Paediatric data Pulmicort Turbuhaler Powder for inhalation 100 µg, 200 µg, 400 µg Budesonide Marketing Autorisation Holder:
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationClinical review. Asthma programme in Finland: a community problem needs community solutions
86 Thorax 21;56:86 814 Clinical review Division of Allergy, Skin and Allergy Hospital, Helsinki University Central Hospital, 29 HUS, Finland T Haahtela Social Insurance Institution, Helsinki T Klaukka
More informationASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 ASTHMA TREATMENT EFFICACY ASSESSMENT BY FeNO MEASUREMENT Dana ALEXANDRESCU 1 Abstract: The author of
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationAirway remodeling in childhood asthma: Menace or myth? Paul L.P. Brand
Airway remodeling in childhood asthma: Menace or myth? Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Definition Airway remodeling in asthmatic
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationEmily DiMango, MD Asthma II
Emily DiMango, MD Asthma II Director John Edsall/John Wood Asthma Center Columbia University Medical Center HP 2000 Goal: 2.25/1,000 Comparison of Asthma Hospitalization Rates in Children Aged 0-14 in
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationMODERATE PERSISTENT ASTHMA IN CHILDREN; COMPARISON OF INHALED BECLOMETHASONE WITH ORAL MONTELUKAST IN THE MANAGEMENT
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2495 MODERATE PERSISTENT ASTHMA IN CHILDREN; COMPARISON OF INHALED BECLOMETHASONE WITH ORAL MONTELUKAST IN THE MANAGEMENT 1 2 3 Dr.
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationA sthma is a chronic inflammatory respiratory disease
15 ASTHMA Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex A Dijkstra, J M Vonk, H Jongepier, G H Koppelman, J P Schouten, N H T ten Hacken, W Timens, D S Postma...
More informationTHE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP?
THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP? Peter S. Creticos, MD ABSTRACT In 1991 and 1997, the National Heart, Lung, and Blood Institute s National Asthma Education
More informationUSEFULNESS OF BRONCHOSCOPY IN CHILDREN: CLINICAL OR RESEARCH TOOL?
USEFULNESS OF BRONCHOSCOPY IN CHILDREN: CLINICAL OR RESEARCH TOOL? Kristiina Malmström 1, Harry Lindahl 2 and Mika J. Mäkelä 1 1. Dept. of Allergy, Helsinki University Central Hospital, Helsinki, Finland
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationWhich asthma patient has allergic airway inflammation?
Which asthma patient has allergic airway inflammation? C o n t r o l l i n g A l l e r g i c A s t h m a Several underlying diseases can present symptoms similar to asthma. Therefore, a correct diagnos
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationPractical Approach to Managing Paediatric Asthma
Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis
More informationHOW I MANAGE THE DIFFICULT ASTHMATIC *
Proc R Coll Physicians Edinb 1997; 27: 194-201 HOW I MANAGE THE DIFFICULT ASTHMATIC * G. K. Crompton, Respiratory Unit, Western General Hospital, Edinburgh The vast majority of patients suffering from
More informationasthma, order-made medicine, phenotypes 2.1 Cluster analysis by Haldar et al.
Received: 8 June 2015 Accepted: 25 February 2016 DOI: 10.1002/jgf2.7 REVIEW ARTICLE Asthma phenotypes Masahiro Hirose MD, PhD Takahiko Horiguchi MD, PhD Department of Respiratory Medicine II, Fujita Health
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationThe natural history of asthma and early intervention
The natural history of asthma and early intervention Stanley J. Szefler, MD Denver, Colo The understanding of the natural history of asthma has changed significantly during the last 4 decades, with the
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationPathology of Asthma Epidemiology
Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationCLINICAL PRACTICE. Clinical Practice. N Engl J Med, Vol. 345, No. 17 October 25,
CLINICAL PRACTICE Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationAdd on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationManagement of wheeze in pre-school children. Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne
Management of wheeze in pre-school children Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne General Practitioner encounters for asthma Asthma in Australia, 2003 Emergency
More informationWheeze and asthma in the very young
EARN 3 FREE CPD POINTS asthma Leader in digital CPD for Southern African healthcare professionals Wheeze and asthma in the very young Insights on diagnosis and current care Professor Felix Ratjen Head:
More informationPCRS-UK briefing document Asthma guidelines. November 2017
PCRS-UK briefing document Asthma guidelines November 2017 1 1. Background The Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) have been collaborating on producing
More informationIntermittent Inhaled Corticosteroids in Infants with Episodic Wheezing
The new england journal of medicine original article Intermittent Inhaled Corticosteroids in Infants with Episodic Wheezing Hans Bisgaard, M.D., D.M.Sci., Mette Northman Hermansen, M.D., Lotte Loland,
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationHappy Wheezer/Happy Parent/ Happy Doctor (?)
Happy Wheezer/Happy Parent/ Happy Doctor (?) Andrew Bush MD FRCP FRCPCH FERS Imperial College & Royal Brompton Hospital a.bush@imperial.ac.uk Conflict of Interest AB has no financial or other COI There
More informationAsthma. Jill Waldron Respiratory Specialist Nurse
Asthma Jill Waldron Respiratory Specialist Nurse Asthma morbidity 15 20% of children In a class of c30 children likely to be 4-54 children with asthma In infancy more common in boys but becomes more common
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationRecurrent Wheezing in Preschool Children. William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology
Recurrent Wheezing in Preschool Children William Sheehan, MD Associate Professor of Pediatrics Division of Allergy and Immunology Disclosure I have nothing to disclose related to this talk. Background
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationBronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013
Bronchial asthma E. Cserháti 1 st Department of Paediatrics Lecture for english speaking students 5 February 2013 Epidemiology of childhood bronchial asthma Worldwide prevalence of 7-8 and 13-14 years
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationTo Study the Prescribing Pattern of Respiratory Distress Associated with Wheezing in Pediatric Patients
To Study the Prescribing Pattern of Respiratory Distress Associated with Wheezing in Pediatric Patients Jocy Mathew 1, Dr. R. Ramanathan 2 1 Pharm D. [Intern], Department of Pharmacy, Annamalai University,
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationAsthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
More informationAsthma in Children with Sickle Cell Disease
December 18, 2018 Asthma in Children with Sickle Cell Disease Robyn Cohen, MD, MPH Director, Division of Pediatric Pulmonology and Allergy Associate Professor of Pediatrics Boston University/Boston Medical
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More information